Last reviewed · How we verify

PREMPRO/PREMPHASE (CONJUGATED ESTROGENS/MEDROXYPROGESTERONE ACETATE)

WYETH AYERST · FDA-approved approved Quality 6/100

PREMPRO/PREMPHASE (generic name: CONJUGATED ESTROGENS/MEDROXYPROGESTERONE ACETATE) is a drug developed by WYETH AYERST. It is currently FDA-approved.

At a glance

Generic nameCONJUGATED ESTROGENS/MEDROXYPROGESTERONE ACETATE
SponsorWYETH AYERST
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about PREMPRO/PREMPHASE

What is PREMPRO/PREMPHASE?

PREMPRO/PREMPHASE (CONJUGATED ESTROGENS/MEDROXYPROGESTERONE ACETATE) is a pharmaceutical drug developed by WYETH AYERST.

Who makes PREMPRO/PREMPHASE?

PREMPRO/PREMPHASE is developed and marketed by WYETH AYERST (see full WYETH AYERST pipeline at /company/wyeth-ayerst).

What is the generic name of PREMPRO/PREMPHASE?

CONJUGATED ESTROGENS/MEDROXYPROGESTERONE ACETATE is the generic (nonproprietary) name of PREMPRO/PREMPHASE.

What development phase is PREMPRO/PREMPHASE in?

PREMPRO/PREMPHASE is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing